Core Insights - Shanghai United Imaging Healthcare Co., Ltd. won the first prize at the 2024 Shanghai Science and Technology Progress Award for its project on the independent research and industrialization of multimodal molecular imaging equipment, highlighting its technological advancements in the field [1] - The company aims to enhance product performance and accessibility of medical services, driven by clinical and research needs [1] Product Performance and Innovation - The project developed the world's first full-body PET/CT, which has nearly 40 times the sensitivity of traditional devices and can complete full-body imaging in seconds, providing new technical support for systemic diseases, drug development, and cancer micro-metastasis research [2] - The project established a vertical innovation system that supports continuous innovation of domestic molecular imaging products and enhances their influence in the global medical imaging industry [2] - The integrated PET/MR system is the first in China and the second in the world with time-of-flight (TOF) capabilities, enabling real-time data collection from both MR and PET modalities, crucial for early diagnosis of complex diseases [3] Technological Breakthroughs - The project overcame key technological challenges in large-size LYSO crystal growth, PET-specific chips, high-performance digital PET detectors, and integrated PET/CT and PET/MR systems, achieving breakthroughs in spatial and temporal resolution [4] - The molecular imaging team pioneered a modular multi-unit architecture to address engineering challenges, significantly enhancing clinical application levels [4][5] Clinical Applications and Research Contributions - The project has established imaging and diagnostic protocols based on over 40,000 tumor clinical images collected from ten major hospitals, promoting standardized clinical applications of full-body PET/CT [5] - Research based on the full-body PET/CT has provided new paradigms for multi-parameter imaging applications and demonstrated its potential in supporting targeted therapy drug research [5] - The company's molecular imaging products have led to over 380 published papers by experts, with many appearing in top journals in the field [5] Market Presence and Recognition - The project has received 13 national Class III medical device registrations and 12 certifications from the US and EU, with over 600 molecular imaging devices installed globally, covering nearly 30 countries [6] - The PET/CT product has maintained the number one market share in China's molecular imaging market for nine consecutive years, while the PET/MR product achieved a 60% market share in 2022 [6]